---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-23-000059"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:03:49.857847+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lifecore Q2 FY2023 net loss $12.4M; revenue down 11% to $38.8M; initiates strategic alternatives review

## Summary
- Revenue $38.8M, down 11% YoY; net loss $12.4M vs net income $4.2M a year ago.
- Adjusted EBITDA $(0.4)M compared to $8.2M; Lifecore segment EBITDA $3.0M vs $9.1M.
- Board initiates strategic alternatives review; retains Morgan Stanley; contingent on lender forbearance.
- Signed term sheet with existing customer for substantial expansion including up-front payments.
- Development pipeline grew to 25 active projects; 3 projects received FDA approval, expanding commercial products to 29.

## SEC filing metadata
- accession: 0001005286-23-000059
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528623000059/0001005286-23-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528623000059/lndc-20230316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-23-000059
- JSON: https://secwatch.observer/filing/0001005286-23-000059.json
- Plain text: https://secwatch.observer/filing/0001005286-23-000059.txt

## Key facts
- Earnings Releases
  LIFECORE BIOMEDICAL, INC. DE reported the fiscal 2023 second quarter ended November 27, 2022 results: revenue $38.8 million, net income $(12.4) million, EPS $(0.42) per diluted share.
  - Period: the fiscal 2023 second quarter ended November 27, 2022
  - Revenue: $38.8 million
  - Net income: $(12.4) million
  - EPS: $(0.42) per diluted share
  - Result: reported results
  source text: Foods assets are reflected as part of the Curation Foods segment in all periods presented within the Company’s financial statements reported herein. • Consolidated revenues of $38.8 million, a decrease of (10.7)% year-over-year. • Consolidated gross profit of $7.1 million, a decrease of $7.6 million, or 51.7% year-over-year, primarily due to a $5.0 million decline
  evidence_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528623000059/0001005286-23-000059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.